DrugInvestigational line
Bortezomib
Proteasome inhibitor (NF-κB pathway)
- Response rate
- Single case report
- Onset
- Unknown
- Route
- SC or IV
- Line
- Investigational
- IgM effect
- Unknown
- Evidence level
- default
Evidence summary
Novel approach targeting the NF-κB pathway. Bai et al. 2025 reported use in a patient without detectable serum IL-1β who was negative for monogenic autoinflammatory variants and MYD88 L265P. Very preliminary.
Approved indications
Conditions for which Bortezomib has regulatory approval (not specific to rare diseases covered here):
Multiple MyelomaMantle Cell Lymphoma
Drug identifiers
| DrugBank | DB00188 ↗ |
| ATC Code | L01XG01 |
| Open Targets | CHEMBL325041 ↗ |
Molecular targets
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| NF-κB | Master transcription factor | Persistently active | strong |